

DAFTAR PUSTAKA

- Ambroz, D., Jansa, P., Kuchar, J., Belohlavek, J., Aschermann, M., *et al.*, 2020. Predictors of survival in patients with pulmonary hypertension and acute right heart failure. *Bratislava Medical Journal* 121. doi:10.4149/BLL_2020_035
- Ancion, A., Allepaerts, S., Oury, C., Gori, A.S., Piérard, L.A., *et al.*, 2017. Serum albumin level and hospital mortality in acute non-ischemic heart failure. *ESC Heart Fail* 4. doi:10.1002/ehf2.12128
- Anderson, J.J., & Lau, E.M., 2022. Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia. *JACC: Asia*. doi:10.1016/j.jacasi.2022.04.008
- Anderson, J.J., Lau, E.M., Lavender, M., Benza, R., Celermajer, D.S., *et al.*, 2020. Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort. *Chest* 157. doi:10.1016/j.chest.2019.08.2203
- Baumgartner, H., de Backer, J., Babu-Narayan, S. V., Budts, W., Chessa, M., *et al.*, 2021. 2020 ESC Guidelines for the management of adult congenital heart disease. *Eur Heart J*. doi:10.1093/eurheartj/ehaa554
- Benmachiche, M., Marques-Vidal, P., Waeber, G., & Méan, M., 2018. In-hospital mortality is associated with high NT-proBNP level. *PLoS One* 13. doi:10.1371/journal.pone.0207118
- Benza, R.L., Miller, D.P., Barst, R.J., Badesch, D.B., Frost, A.E., *et al.*, 2012. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. *Chest* 142. doi:10.1378/chest.11-1460
- Benza, R.L., Miller, D.P., Gomberg-Maitland, M., Frantz, R.P., Foreman, A.J., *et al.*, 2010. Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). *Circulation* 122. doi:10.1161/CIRCULATIONAHA.109.898122
- Bhatnagar, A., Wiesen, J., Dweik, R., & Chaisson, N.F., 2018. Evaluating suspected pulmonary hypertension: A structured approach. *Cleve Clin J Med*. doi:10.3949/ccjm.85a.17065
- Bhattacharya, P.T., Hameed, A.M.A., Bhattacharya, S.T., Chirinos, J.A., Hwang, W.T., *et al.*, 2020. Risk factors for 30-day readmission in adults hospitalized for pulmonary hypertension. *Pulm Circ* 10. doi:10.1177/2045894020966889
- Boucly, A., Savale, L., Jaïs, X., Bauer, F., Bergot, E., *et al.*, 2021. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 204. doi:10.1164/rccm.202009-3698OC



- Burger, C.O., Long, P.K., Romero, A.J., Benton, W.W., & Safford, R.E., 2014. Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry. *Chest* 146: 1263–1273. doi:10.1378/chest.14-0193
- Campo, A., Mathai, S.C., Le Pavec, J., Zaiman, A.L., Hummers, L.K., *et al.*, 2011. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. *European Respiratory Journal* 38. doi:10.1183/09031936.00148310
- Cao, Z., Jia, Y., & Zhu, B., 2019. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. *Int J Mol Sci*. doi:10.3390/ijms20081820
- Caraballo, C., Desai, N.R., Mulder, H., Alhanti, B., Wilson, F.P., *et al.*, 2019. Clinical Implications of the New York Heart Association Classification. *J Am Heart Assoc* 8. doi:10.1161/JAHA.119.014240
- Chakinala, M.M., & Barst, R., 2013. From short-term benefits to long-term outcomes: The evolution of clinical trials in pulmonary arterial hypertension. *Pulm Circ*. doi:10.1086/674456
- Chakinala, M.M., Coyne, D.W., Benza, R.L., Frost, A.E., McGoon, M.D., *et al.*, 2018. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. *Journal of Heart and Lung Transplantation* 37: 696–705. doi:10.1016/j.healun.2017.10.028
- Chen, S.L., Zhang, H., Xie, D.J., Zhang, J., Zhou, L., *et al.*, 2017. Pericardial effusion is correlated with clinical outcome after pulmonary artery denervation for pulmonary arterial hypertension. *Oncotarget* 8. doi:10.18632/oncotarget.14031
- Corciova, F.C., Arsenescu -Georgescu, C., & Georgescu, G., 2012. Maedica-a Journal of Clinical Medicine Prognostic Factors in Pulmonary Hypertension, Maedica A Journal of Clinical Medicine.
- D'Alto, M., Scognamiglio, G., Dimopoulos, K., Bossone, E., Vizza, D., *et al.*, 2015. Right heart and pulmonary vessels structure and function. *Echocardiography* 32. doi:10.1111/echo.12227
- De Filippo, O., Gatti, P., Rettengo, S., Iannaccone, M., D'Ascenzo, F., *et al.*, 2019. Is pericardial effusion a negative prognostic marker? Meta-analysis of outcomes of pericardial effusion. *Journal of Cardiovascular Medicine* 20. doi:10.2459/JCM.0000000000000720
- Dinarti, L.K., Anggrahini, D.W., Lilyasari, O., Siswanto, B.B., & Hartopo, A.B., 2021. Pulmonary arterial hypertension in Indonesia: Current status and local application of international guidelines. *Glob Heart*. doi:10.5334/GH.944
- Dinarti, L.K., Hartopo, A.B., Kusuma, A.D., Satwiko, M.G., Hadwiono, M.R., *et al.*, 2020. The COngenital HeARt Disease in adult and Pulmonary



- Hypertension (COHARD-PH) registry: A descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. *BMC Cardiovasc Disord* 20. doi:10.1186/s12872-020-01434-z
- Dolara, A., Camerini, F., Menotti, A., & Thiene, G., 1988. Primary pulmonary hypertension: an Italian multicenter study. A retrospective epidemiological survey in the period 1975-1985. *G Ital Cardiol* 18.
- Emmons-Bell, S., Johnson, C., Boon-Dooley, A., Corris, P.A., Leary, P.J., *et al.*, 2022. Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study. *Pulm Circ* 12. doi:10.1002/pul2.12020
- Fijalkowska, A., Kurzyna, M., Torbicki, A., Szewczyk, G., Florczyk, M., *et al.*, 2006. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest* 129: 1313–1321. doi:10.1378/chest.129.5.1313
- Forfia, P.R., Mathai, S.C., Fisher, M.R., Houston-Harris, T., Hemnes, A.R., *et al.*, 2008. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 177. doi:10.1164/rccm.200712-1876OC
- Frost, A., Badesch, D., Gibbs, J.S.R., Gopalan, D., Khanna, D., *et al.*, 2019. Diagnosis of pulmonary hypertension. *European Respiratory Journal* 53: 1801904. doi:10.1183/13993003.01904-2018
- Frost, A.E., Badesch, D.B., Miller, D.P., Benza, R.L., Meltzer, L.A., *et al.*, 2013. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: A REVEAL registry analysis. *Chest* 144: 1521–1529. doi:10.1378/chest.12-3023
- Galiè, N., Humbert, M., Vachiery, J.L., Gibbs, S., Lang, I., *et al.*, 2015. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* 37. doi:10.1093/eurheartj/ehv317
- Gall, H., Felix, J.F., Schneck, F.K., Milger, K., Sommer, N., *et al.*, 2017. The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. *Journal of Heart and Lung Transplantation* 36. doi:10.1016/j.healun.2017.02.016
- Ha, C.E., & Bhagavan, N. V., 2013. Novel insights into the pleiotropic effects of human serum albumin in health and disease. *Biochim Biophys Acta Gen Subj*. doi:10.1016/j.bbagen.2013.04.012
- Haddad, F., Peterson, T., Fuh, E., Kudelko, K.T., De Jesus Perez, V., *et al.*, 2011. Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. *Circ Heart Fail* 4. doi:10.1161/CIRCHEARTFAILURE.110.949933



- Harder, E.M., Small, A.M., & Fares, W.H., 2020. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. *Respir Med* 161. doi:10.1016/j.rmed.2019.105850
- Hartopo, A.B., Anggrahini, D.W., Dinarti, L.K., Schäfer, A.K., Bergmann, A., *et al.*, 2023. Prognostic Value for Mortality of Plasma Bioactive Adrenomedullin in Patients with Pulmonary Arterial Hypertension: A Sub Analysis of the Biomarker Study in the COHARD-PH Registry. *Medicina (Lithuania)* 59. doi:10.3390/medicina59040748
- Heidenreich, P.A., Bozkurt, B., Aguilar, D., Allen, L.A., Byun, J.J., *et al.*, 2022. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 79: e263–e421. doi:10.1016/j.jacc.2021.12.012
- Hendriks, P.M., Staal, D.P., van de Groep, L.D., van den Toorn, L.M., Chandoesing, P.P., *et al.*, 2022a. The evolution of survival of pulmonary arterial hypertension over 15 years. *Pulm Circ* 12. doi:10.1002/pul2.12137
- Hendriks, P.M., van de Groep, L.D., Veen, K.M., van Thor, M.C.J., Meertens, S., *et al.*, 2022b. Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and meta-analysis. *Am Heart J*. doi:10.1016/j.ahj.2022.05.006
- Hilliker, K.S., Bell, T.G., Lorimer, D., & Roth, R.A., 1984. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension. *Am J Physiol Heart Circ Physiol* 15. doi:10.1152/ajpheart.1984.246.6.h747
- Hojda, S.E., Chis, I.C., & Clichici, S., 2022. Biomarkers in Pulmonary Arterial Hypertension. *Diagnostics*. doi:10.3390/diagnostics12123033
- Howard, L.S., 2011. Prognostic factors in pulmonary arterial hypertension: Assessing the course of the disease. *European Respiratory Review*. doi:10.1183/09059180.00006711
- Hu, B., Xu, G., Jin, Xin, Chen, D., Qian, X., *et al.*, 2021. Novel Prognostic Predictor for Primary Pulmonary Hypertension: Focus on Blood Urea Nitrogen. *Front Cardiovasc Med* 8. doi:10.3389/fcvm.2021.724179
- Humbert, M., Kovacs, G., Hoeper, M.M., Badagliacca, R., Berger, R.M.F., *et al.*, 2023. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *European Respiratory Journal*. doi:10.1183/13993003.00879-2022
- Humbert, M., Kovacs, G., Hoeper, M.M., Badagliacca, R., Berger, R.M.F., *et al.*, 2022. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. doi:10.1093/eurheartj/ehac237



- Humbert, M., Sitbon, O., Yaïci, A., Montani, D., O’Callaghan, D.S., *et al.*, 2010. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. *European Respiratory Journal* 36. doi:10.1183/09031936.00057010
- Kaemmerer, H., Gorenflo, M., Huscher, D., Pittrow, D., Apitz, C., *et al.*, 2020. Pulmonary hypertension in adults with congenital heart disease: Real-world data from the international compera-chd registry. *J Clin Med* 9. doi:10.3390/jcm9051456
- Kohyama, T., Moriyama, K., Kanai, R., Kotani, M., Uzawa, K., *et al.*, 2015. Accuracy of pulse oximeters in detecting hypoxemia in patients with chronic thromboembolic pulmonary hypertension. *PLoS One* 10. doi:10.1371/journal.pone.0126979
- Kozu, K., Sugimura, K., Aoki, T., Tatebe, S., Yamamoto, S., *et al.*, 2018. Sex differences in hemodynamic responses and long-term survival to optimal medical therapy in patients with pulmonary arterial hypertension. *Heart Vessels* 33: 939–947. doi:10.1007/s00380-018-1140-6
- Krasuski, R.A., Hart, S.A., Smith, B., Wang, A., Harrison, J.K., *et al.*, 2011. Association of anemia and long-term survival in patients with pulmonary hypertension. *Int J Cardiol* 150. doi:10.1016/j.ijcard.2010.04.038
- Kuang, H., Li, Q., Yi, Q., & Lu, T., 2019. The Efficacy and Safety of Aerosolized Iloprost in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. *American Journal of Cardiovascular Drugs* 19. doi:10.1007/s40256-018-00324-2
- Kutsch, J., Faul, C., von Scheidt, W., Schwaiblmair, M., & Berghaus, T.M., 2018. The association of the N-terminal pro-brain-type natriuretic peptide response to exercise with disease severity in therapy-naïve pulmonary arterial hypertension: A cohort study. *Respir Res*. doi:10.1186/s12931-017-0712-9
- Lan, N.S.H., Massam, B.D., Kulkarni, S.S., & Lang, C.C., 2018. Pulmonary Arterial Hypertension: Pathophysiology and Treatment. *Diseases* 6. doi:10.3390/diseases6020038
- Leber, L., Beaudet, A., & Muller, A., 2021. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. *Pulm Circ* 11. doi:10.1177/2045894020977300
- Lim, Y., Low, T.T., Chan, S.P., Teo, T.W., Jang, J.H.J., *et al.*, 2019. Pulmonary arterial hypertension in a multi-ethnic Asian population: Characteristics, survival and mortality predictors from a 14-year follow-up study. *Respirology* 24: 162–170. doi:10.1111/resp.13392
- Lopes, A.A., Barst, R.J., Haworth, S.G., Rabinovitch, M., Al Dabbagh, M., *et al.*, 2014. Repair of congenital heart disease with associated pulmonary

- hypertension in children: What are the minimal investigative procedures? Consensus statement from the congenital heart disease and pediatric task forces, pulmonary vascular research institute (PVRI). *Pulm Circ* 4: 330–341. doi:10.1086/675995
- Maron, B.A., 2023. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. *J Am Heart Assoc*. doi:10.1161/JAHA.122.029024
- Maurer, S.J., Habdank, V., Hörer, J., Ewert, P., & Tutarel, O., 2023. NT-proBNP Is a Predictor of Mortality in Adults with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. *J Clin Med* 12. doi:10.3390/jcm12093101
- McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., *et al.*, 2021. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 42: 3599–3726. doi:10.1093/eurheartj/ehab368
- Naeije, R., & Huez, S., 2007. Right ventricular function in pulmonary hypertension: Physiological concepts. *European Heart Journal, Supplement* 9. doi:10.1093/eurheartj/sum023
- Nashat, H., Montanaro, C., Li, W., Kempny, A., Wort, S.J., *et al.*, 2018. Atrial septal defects and pulmonary arterial hypertension. *J Thorac Dis*. doi:10.21037/jtd.2018.08.92
- Nickel, N.P., Galura, G.M., Zuckerman, M.J., Hakim, M.N., Alkhateeb, H., *et al.*, 2021. Liver abnormalities in pulmonary arterial hypertension. *Pulm Circ*. doi:10.1177/20458940211054304
- Nowroozpoor, A., Malekmohammad, M., Seyyedi, S.R., & Hashemian, S.M., 2019. Pulmonary hypertension in intensive care units: An updated review. *Tanaffos*.
- Oishi, P., & Fineman, J.R., 2016. Pulmonary Hypertension. *Pediatric Critical Care Medicine* 17.
- Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., *et al.*, 2002. Inhaled Iloprost for Severe Pulmonary Hypertension. *New England Journal of Medicine* 347. doi:10.1056/nejmoa020204
- Opitz, C.F., Wensel, R., Winkler, J., Halank, M., Bruch, L., *et al.*, 2005. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. *Eur Heart J* 26. doi:10.1093/eurheartj/ehi283
- Paciocco, G., Martinez, F.J., Bossone, E., Pielsticker, E., Gillespie, B., *et al.*, 2001. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. *European Respiratory Journal* 17. doi:10.1183/09031936.01.17406470



- Palacios-Moguel, P., Cueto-Robledo, G., González-Pacheco, H., Ortega-Hernández, J., Torres-Rojas, M.B., *et al.*, 2025. The role of the TAPSE/sPAP ratio as a predictor of mortality in Pulmonary Arterial Hypertension: Its value for patient risk stratification. *JHLT Open* 7: 100168. doi:10.1016/j.jhlto.2024.100168
- Piao, L., Fang, Y.H., Parikh, K.S., Ryan, J.J., D'Souza, K.M., *et al.*, 2012. GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: Therapeutic implications in pulmonary hypertension. *Circulation* 126. doi:10.1161/CIRCULATIONAHA.112.109868
- Rabinovitz, A., Raiszadeh, F., & Zolty, R., 2013. Association of hyponatremia and outcomes in pulmonary hypertension. *J Card Fail* 19. doi:10.1016/j.cardfail.2013.05.014
- Radchenko, G.D., Zhyvylo, I.O., & Sirenko, Y.M., 2019. Analysis of pulmonary hypertension patient survival after treatment in referral center (data of first Ukrainian register). *Pulm Circ* 9. doi:10.1177/2045894019845604
- Raymond, R.J., Hinderliter, A.L., Willis, P.W., Ralph, D., Caldwell, E.J., *et al.*, 2002. Echocardiographic Predictors of Adverse Outcomes in Primary Pulmonary Hypertension, *Journal of the American College of Cardiology*.
- Rejeki, V.G., Widyantoro, B., Zamroni, D., Habib, F., & Bagaswoto, H.P., 2021. HIPERTENSI PULMONAL, Pertama. ed. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
- Rich, S., & Levy, P.S., 1984. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. *Am J Med* 76. doi:10.1016/0002-9343(84)90279-1
- Rosenkranz, S., Howard, L.S., Gomberg-Maitland, M., & Hoeper, M.M., 2020. Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. *Circulation* 141. doi:10.1161/CIRCULATIONAHA.116.022362
- Rudkovskaia, A.A., Tonelli, A.R., Rao, Y., Hammel, J.P., Buller, G.K., *et al.*, 2018. Is hyponatremia associated with mortality in pulmonary arterial hypertension? *Pulm Circ* 8. doi:10.1177/2045894018776888
- Rudkovskaiia, A.A., Tonelli, A.R., Rao, Y., Dweik, R.A., & Fares, W.H., 2017. Prognostic value of the baseline serum sodium level in 2 independent cohorts of pulmonary arterial hypertension. *Pulm Circ* 7.
- Rudski, L.G., Lai, W.W., Afilalo, J., Hua, L., Handschumacher, M.D., *et al.*, 2014. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography. *ARQUIVOS BRASILEIROS DE CARDIOLOGIA - IMAGEM CARDIOVASCULAR* 27. doi:10.5935/2318-8219.20140013
- Rush, B., Biagioni, B.J., Berger, L., & McDermid, R., 2017. Mechanical Ventilation Outcomes in Patients With Pulmonary Hypertension in the United

- States: A National Retrospective Cohort Analysis. *J Intensive Care Med* 32. doi:10.1177/0885066616653926
- Sato, T., Tsujino, I., Ohira, H., Oyama-Manabe, N., Yamada, A., *et al.*, 2012. Validation study on the accuracy of echocardiographic measurements of right ventricular systolic function in pulmonary hypertension. *Journal of the American Society of Echocardiography* 25. doi:10.1016/j.echo.2011.12.012
- Savale, L., Weatherald, J., Jaïs, X., Vuillard, C., Boucly, A., *et al.*, 2017. Acute decompensated pulmonary hypertension. *European Respiratory Review* 26. doi:10.1183/16000617.0092-2017
- Shah, S.J., Thenappan, T., Rich, S., Tian, L., Archer, S.L., *et al.*, 2008. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. *Circulation* 117. doi:10.1161/CIRCULATIONAHA.107.719500
- Simonneau, G., Montani, D., Celermajer, D.S., Denton, C.P., Gatzoulis, M.A., *et al.*, 2019. Haemodynamic definitions and updated clinical classification of pulmonary hypertension, in: *European Respiratory Journal*. doi:10.1183/13993003.01913-2018
- Snipelisky, D., Jentzer, J., Batal, O., Dardari, Z., & Mathier, M., 2018. Serum albumin concentration as an independent prognostic indicator in patients with pulmonary arterial hypertension. *Clin Cardiol* 41. doi:10.1002/clc.22954
- Sompradeekul, S., & Wattanasiriphakdee, S., 2015. Hemodynamic effect of iloprost inhalation and oral sildenafil during acute vasoreactivity test in pulmonary arterial hypertension. *Journal of the Medical Association of Thailand* 98.
- Sonnweber, T., Pizzini, A., Tancevski, I., Löffler-Ragg, J., & Weiss, G., 2020. Anaemia, iron homeostasis and pulmonary hypertension: a review. *Intern Emerg Med*. doi:10.1007/s11739-020-02288-1
- Steiner, J., Wu, W.C., Jankowich, M., Maron, B.A., Sharma, S., *et al.*, 2015. Echocardiographic predictors of mortality in patients with pulmonary hypertension and cardiopulmonary comorbidities. *PLoS One* 10. doi:10.1371/journal.pone.0119277
- Stepnowska, E., Lewicka, E., Dąbrowska-Kugacka, A., Daniłowicz-Szymanowicz, L., Zagożdżon, P., *et al.*, 2018. Predictors of poor outcome in patients with pulmonary arterial hypertension: A single center study. *PLoS One* 13. doi:10.1371/journal.pone.0193245
- Sudaka, A., Teglas, J.-P., Bonnet, D., & Cohen, S., 2024. Predictors of death in patients with pulmonary hypertension associated with pre-tricuspid shunt. *Arch Cardiovasc Dis* 117. doi:10.1016/j.acvd.2023.10.238



- Sztrymf, B., Souza, R., Bertoletti, L., Jaïs, X., Sitbon, O., *et al.*, 2010. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. *European Respiratory Journal* 35. doi:10.1183/09031936.00070209
- Thenappan, T., Ormiston, M.L., Ryan, J.J., & Archer, S.L., 2018. Pulmonary arterial hypertension: Pathogenesis and clinical management. *BMJ (Online)*. doi:10.1136/bmj.j5492
- Thiwanka Wijeratne, D., Lajkosz, K., Brogly, S.B., Diane Lougheed, M., Jiang, L., *et al.*, 2018. Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada. *Circ Cardiovasc Qual Outcomes* 11. doi:10.1161/CIRCOUTCOMES.117.003973
- Tonelli, A.R., Arelli, V., Minai, O.A., Newman, J., Bair, N., *et al.*, 2013. Causes and circumstances of death in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 188. doi:10.1164/rccm.201209-1640OC
- Topyła-Putowska, W., Tomaszewski, M., Wysokiński, A., & Tomaszewski, A., 2021. Echocardiography in pulmonary arterial hypertension: Comprehensive evaluation and technical considerations. *J Clin Med*. doi:10.3390/jcm10153229
- Van Der Feen, D.E., Bartelds, B., De Boer, R.A., & Berger, R.M.F., 2019. Assessment of reversibility in pulmonary arterial hypertension and congenital heart disease. *Heart*. doi:10.1136/heartjnl-2018-314025
- Vijarnsorn, C., Durongpisitkul, K., Chungsomprasong, P., Bositthipichet, D., Ketsara, S., *et al.*, 2018. Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts. *PLoS One* 13. doi:10.1371/journal.pone.0195092
- Wang, D., Huang, S., Xu, G., Wu, S., Liu, Z., *et al.*, 2022a. Abnormal Liver Function Tests Were Related to Short- and Long-Term Prognosis in Critically Ill Patients With Primary Pulmonary Hypertension. *Front Cardiovasc Med* 9. doi:10.3389/fcvm.2022.897040
- Wang, D., Huang, S., Xu, G., Wu, S., Liu, Z., *et al.*, 2022b. Abnormal Liver Function Tests Were Related to Short- and Long-Term Prognosis in Critically Ill Patients With Primary Pulmonary Hypertension. *Front Cardiovasc Med* 9. doi:10.3389/fcvm.2022.897040
- Wang, R.C., Jiang, F.M., Zheng, Q.L., Li, C.T., Peng, X.Y., *et al.*, 2014. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: A systematic review. *Respir Med* 108. doi:10.1016/j.rmed.2014.01.003
- Winterhalter, M., Rex, S., Stoppe, C., Kienbaum, P., Müller, H.H., *et al.*, 2019. Effect of iloprost inhalation on postoperative outcome in high-risk cardiac surgical patients: a prospective randomized-controlled multicentre trial



(ILOCARD). *Canadian Journal of Anesthesia* 66. doi:10.1007/s12630-019-01309-8

Yolanda, D.A., 2023. Penilaian Right Ventricle – Pulmonary Artery Coupling sebagai Faktor Prediksi Kematian pada Pasien Defek Septum Atrium yang Belum dikoreksi dengan Hipertensi Pulmonal. *Tesis*, Sp.JP., Universitas Gadjah Mada, Yogyakarta.

Zhang, R., Dai, L.Z., Xie, W.P., Yu, Z.X., Wu, B.X., *et al.*, 2011. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. *Chest* 140. doi:10.1378/chest.10-2327